Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R03) | Apply Online

Opportunity Summary:

The Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R03) funding opportunity (PAR-07-447) is an NIH small grant program designed to push early-stage, high-value research in primary immunodeficiency diseases (PIDs). The emphasis is on practical, discovery-oriented studies that can be done on a modest budget and within a short time frame, especially projects that use ex vivo work with human specimens (for example, functional immune assays performed on patient-derived cells or tissues) and studies that rely on existing or newly developed animal models. The FOA also highlights the value of novel clinical strategies, meaning projects aimed at improving how PIDs are detected, clarifying their molecular causes, or laying groundwork for innovative therapies.

The types of projects this R03 is meant to support are typically small, self-contained efforts that generate preliminary data or test a focused idea rather than attempting a large, multi-aim program. Common fits include pilot and feasibility studies, secondary analyses of existing datasets, tightly scoped hypothesis-driven projects, and the development of research methods or enabling technologies. In practice, this could include validating a new diagnostic approach, exploring genotype-phenotype relationships in a defined PID cohort, testing a mechanistic pathway in a relevant mouse model, or creating and benchmarking a new assay or platform that makes PID research more precise or scalable. Because the R03 is an exploratory mechanism, the expectation is often that successful projects will position investigators to pursue larger follow-on awards later.

A notable feature of the announcement is its explicit encouragement for investigators who are new to independent NIH funding, as well as investigators who have not previously held independent NIH support in the PID research space. The intent is to broaden participation and help newer or transitioning researchers establish a foothold in primary immunodeficiency research with a manageable award size and a clear, achievable scope.

In terms of mechanism and relationship to other NIH opportunities, this FOA uses the NIH Small Research Grant (R03) mechanism and is described as running in parallel with a companion announcement of identical scientific scope that uses the R21 mechanism (PAR-07-446). Functionally, the R03 is the smaller, more tightly budgeted option, generally appropriate for a compact study that can be completed within two years, whereas the R21 typically supports a larger exploratory effort. Applicants choose the mechanism that best fits the scale and maturity of their proposed work.

Funding levels and award expectations are clearly defined. NIH anticipated about $0.2 million per year in total funds for this FOA and projected making roughly three new awards each year, assuming funds are available and enough high-quality applications are submitted. For individual projects, applicants may request up to $50,000 per year in direct costs for up to two years, with a maximum of $100,000 in direct costs across the full project period. The R03 under this announcement is not renewable, so it is intended as a one-time, short-duration boost rather than an ongoing funding stream.

Eligibility is broad and includes a wide range of organization types. Eligible applicants include public and private institutions of higher education, many nonprofit organizations (with and without 501(c)(3) status), small businesses and other for-profit organizations (not limited to small businesses), state and local governmental entities, U.S. territories, tribal governments and tribally designated organizations, regional organizations, and eligible federal agencies. Importantly, foreign (non-U.S.) organizations are also eligible to apply, and faith-based or community-based organizations are explicitly included as eligible. This breadth signals NIH interest in attracting strong ideas regardless of institutional type, as long as the applicant can carry out the proposed research.

The FOA is open to any qualified Project Director/Principal Investigator with the appropriate expertise, resources, and institutional support. NIH also reiterates its standard commitment to encouraging applications from underrepresented racial and ethnic groups and from individuals with disabilities. The announcement allows multiple PDs/PIs on a single application, which can be useful for interdisciplinary PID projects that bridge clinical immunology, genetics, bioinformatics, and model-system work.

On submission rules and limits, an individual applicant may serve as PD/PI on only one application submitted in response to this FOA per receipt date, which prevents duplicate or competing submissions by the same lead investigator in the same cycle. At the institutional level, more than one application may be submitted as long as each application is scientifically distinct, allowing departments or centers to put forward multiple separate PID-focused ideas. Resubmission is permitted: up to two resubmissions of a previously reviewed small grant application may be submitted under NIH policy, but the award itself cannot be renewed once funded.

Administratively, this is a discretionary grant opportunity in the NIH health research portfolio, tied to CFDA program areas that include blood diseases and resources research (93.839), allergy/immunology and transplantation research (93.855), and child health and human development extramural research (93.865). The opportunity does not require cost sharing or matching. The FOA was originally posted in September 2007 and had multiple receipt dates, with the final listed closing date in May 2010 and an archive date in June 2010, meaning it is a historical announcement rather than an active, currently open competition. For full details, NIH provided an archived full-announcement link and an NIH Office of Extramural Research contact for access or technical issues.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health Income Security and Social Services

Next opportunity: Epidemiology and Prevention in Alcohol Research (R01)

Previous opportunity: Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 07 447

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 07 447) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 07 447", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.